Turn Future Therapies Into Product Realities

Navigating the complexities of cell and gene therapy manufacturing requires balancing speed, high quality, and cost efficiency. High-titer Lentiviral Vectors (LV) form the backbone of advanced therapies like CAR-T, yet production bottlenecks often delay clinical and commercial milestones. Streamlining vector design and manufacturing reduces timelines significantly, making it possible to advance from initial concept to release of Good Manufacturing Practice (GMP) grade material in just 11 months.

Robust, scalable platform technologies enable seamless transitions from small-scale development (50 mL) to full-scale production (500 mL) while maintaining consistent yields.  A fee-for-service model provides complete freedom to operate, cutting GMP lot costs in half without compromising vector quality or regulatory standards.

Explore how optimized processes accelerate your path to market.